Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sehui Kim

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Journal of Experimental & Clinical Cancer Research : CR|November 14, 2019
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancerSehui Kim, Ji-Young Jang, Jaemoon Koh, et al.
BMC Cancer|January 9, 2019
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitorsRyul Kim, Bhumsuk Keam, Sehui Kim, et al.
Blood Advances|January 16, 2026
Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panelJeemin Yim, Sungyoung Lee, Sehui Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2022
TCF1<sup>+</sup>PD-1<sup>+</sup> tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancerJaemoon Koh, Sehui Kim, Yeon Duk Woo, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2021
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissuesShin Hye Yoo, Jihui Yun, Bhumsuk Keam, et al.
Scientific Reports|May 24, 2019
Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patientsShin Hye Yoo, Bhumsuk Keam, Chan-Young Ock, et al.
Journal for Immunotherapy of Cancer|March 6, 2025
Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancerHyein Jeong, Jaemoon Koh, Sehui Kim, et al.
Oncotarget|February 20, 2016
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinomaChan-Young Ock, Sehui Kim, Bhumsuk Keam, et al.
Oncotarget|December 13, 2017
Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinomaChan-Young Ock, Sehui Kim, Bhumsuk Keam, et al.
Cell|June 4, 2019
Tracing Oncogene Rearrangements in the Mutational History of Lung AdenocarcinomaJake June-Koo Lee, Seongyeol Park, Hansol Park, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Journal of Experimental & Clinical Cancer Research : CR|November 14, 2019
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancerSehui Kim, Ji-Young Jang, Jaemoon Koh, et al.
BMC Cancer|January 9, 2019
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitorsRyul Kim, Bhumsuk Keam, Sehui Kim, et al.
Blood Advances|January 16, 2026
Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panelJeemin Yim, Sungyoung Lee, Sehui Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2022
TCF1<sup>+</sup>PD-1<sup>+</sup> tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancerJaemoon Koh, Sehui Kim, Yeon Duk Woo, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2021
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissuesShin Hye Yoo, Jihui Yun, Bhumsuk Keam, et al.
Scientific Reports|May 24, 2019
Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patientsShin Hye Yoo, Bhumsuk Keam, Chan-Young Ock, et al.
Journal for Immunotherapy of Cancer|March 6, 2025
Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancerHyein Jeong, Jaemoon Koh, Sehui Kim, et al.
Oncotarget|February 20, 2016
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinomaChan-Young Ock, Sehui Kim, Bhumsuk Keam, et al.
Oncotarget|December 13, 2017
Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinomaChan-Young Ock, Sehui Kim, Bhumsuk Keam, et al.
Cell|June 4, 2019
Tracing Oncogene Rearrangements in the Mutational History of Lung AdenocarcinomaJake June-Koo Lee, Seongyeol Park, Hansol Park, et al.
Pageof 8